The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...

As more doctors and patients turn to the latest weight-loss drugs, researchers are trying to figure out which drug is right ...

This writer considers how long it would take an investor to reach a seven-figure sum by maxing out their Stocks and Shares ...

GLP-1s may help reduce alcohol intake among adults with overweight or obesity, according to data presented at the European Congress on Obesity. Researchers conducted a prospective single-center cohort ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Hims & Hers offers rare high growth at value pricing, with DCF models pointing to major upside despite volatility and short ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Pharma companies were mostly left out of the stock market’s broader rally Monday morning on the news that President Donald ...